Rheumatology Medical News about systemic sclerosis;calcinosis;expression of advanced glycation end products

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Expression of advanced glycation end products and their receptor in skin from patients with systemic sclerosis with and without calcinosis
Rheumatology, 06/24/09

Davies CA et al. – Findings suggest a possible contribution of advanced glycation (AGE) Nε-carboxymethyl lysine-(CML) deposition on the extracellular matrix (ECM) in the dermis of the lcSScCal subgroup to the pathogenesis of formation of calcinotic deposits.

Methods

Study was conducted to:
- To establish which tissue components express AGEs and their receptor (RAGE) in skin from pts with SSc, and
- How their expression relates to the disease subtypes and various clinical parameters
Skin punch biopsies were taken from the forearms of:
- 61 SSc pts with lcSSc
- 32 with calcinosis (lcSScCal) and
- 29 w/o lcSSc
- 36 with the dcSSc subtype and 22 healthy control subjects
IHC localization of AGE-CML and RAGE was assessed semi-quantitatively on the microvascular endothelium, dermal fibroblasts and the cutaneous ECM

Results

AGE-CML expression on the papillary dermis ECM of lcSScCal was greater vs control
The reticular dermis of lcSScCal showed increased AGE- CML expression vs controls, dcSSc, and lcSSc
Increased immunostaining for RAGE was seen on the reticular dermis ECM of the lcSScCal group vs controls
lcSScCal subgroup showed correlations for AGE-CML, and to a lesser extent for RAGE, with increased RP duration
No evidence that the expression of AGE-CML or RAGE related to Ab status, clinical or histological skin score or patient age

<< Previous
Aspects relevant for functioning in patients with ankylosing...

Next >>
Immunohistochemical detection of intravascular platelet...